NA
SUPN icon

Navellier & Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Navellier & Associates’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,311
Closed -$821K – 300
2018
Q3 		$821K Buy
16,311
+410
+3% +$20.2K 0.11% 163
2018
Q2 		$952K Buy
+15,901
New +$824K 0.13% 149

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Navellier & Associates's SUPN Position: Q4 2018 in Review

Navellier & Associates sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 16,311 shares — an estimated $821K sold.

Navellier & Associates first reported a position in SUPN in Q2 2018 and held it in 2 quarters. The position peaked at $952K in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Navellier & Associates reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Navellier & Associates sold 16,311 Supernus Pharmaceuticals shares in Q4 2018, an estimated $821K.
  • Navellier & Associates first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Navellier & Associates's Supernus Pharmaceuticals position peaked at $952K in Q2 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Navellier & Associates's 13F filing for Q4 2018, filed 15 Jan 2019.